Symrise (ETR:SY1) used its full-year 2025 results call to outline progress under its “ONE Symrise” strategy and “ONE SYM Transformation” program, while setting a cautious near-term outlook for 2026 amid soft demand in some end markets and continued geopolitical uncertainty.
2025 performance: organic growth, margin expansion, and cash generation
CEO Jean-Yves Parisot described 2025 as a “defining year,” saying the company focused on “execution, efficiency, cash discipline, and strategic transformation” against a backdrop of “soft demand in certain end markets and continued regional volatility.”
On profitability, management highlighted the introduction of adjusted, supplemental non-IFRS measures going forward, including adjusted EBITDA, to improve comparability. Klinger said adjustments in 2025 included a EUR 150 million non-cash impairment related to Swedencare and a EUR 148 million revaluation and reclassification of the Terpenes business (described as EBITDA-neutral), as well as smaller items tied to portfolio optimization, the ONE SYM Transformation program, and antitrust investigation-related costs.
Adjusted EBITDA margin expanded by 120 basis points in 2025, which management attributed to product mix and execution of cost savings under the transformation program. The company delivered EUR 50 million of incremental profit from efficiency initiatives in 2025, above its EUR 40 million target, after achieving EUR 50 million in 2024 as well.
Symrise also emphasized cash generation. The company reported EUR 780 million in (adjusted) business free cash flow and expanded the adjusted business free cash flow margin by 220 basis points to 15.8%, which it called a record. Management linked the improvement to higher EBITDA, lower CapEx intensity, and disciplined working capital management, including targeted inventory reductions. Net working capital was 32.5% of last-12-month sales.
Segment highlights: Taste, Nutrition & Health and Scent & Care
In Taste, Nutrition & Health, Symrise reported organic growth of 2.6% and reported sales of EUR 3.0 billion. Klinger said growth was supported by food and beverage performance in beverages, Naturals, and Savory, while pet food was flat year-on-year. Adjusted EBITDA for the segment rose 5.2% to EUR 722 million, and adjusted EBITDA margin increased 160 basis points to 23.8%, which management said reflected profitable sales growth, portfolio mix, and efficiency gains.
In Scent & Care, the company reported organic growth of 3.2% on reported sales of EUR 1.901 billion, with foreign exchange described as a headwind of 3.5%. Management said fragrance delivered high single-digit organic growth across Fine Fragrances and Consumer Fragrances, while cosmetic ingredients posted a low single-digit decline due to tough comparables in UV filters; Micro Protection continued to grow. Adjusted EBITDA rose 3.5% to EUR 359 million, and the adjusted EBITDA margin improved 70 basis points to 18.9%.
Cost savings drivers, balance sheet, and shareholder returns
Management broke down the EUR 50 million in 2025 savings and efficiency gains as follows:
- EUR 35 million from sourcing and procurement scale (with citrus cited as an example)
- EUR 10 million from productivity and capacity optimization
- EUR 5 million from global asset and logistics management actions (facility optimization, distribution, contract renegotiation, and logistics centers)
On the balance sheet, net debt including pension provisions and leases was EUR 2.1 billion, and net debt to adjusted EBITDA declined to 1.9x. Symrise also said it received inaugural investment-grade ratings from S&P Global and Moody’s at BBB+ and Baa1, respectively, both with stable outlooks, and updated its long-term leverage target range to 1.5x to 2.5x.
Adjusted EPS for 2025 was EUR 3.67, up 7.2% year over year, while EPS without adjusting for the Swedencare and Safene write-downs was EUR 1.78. The company proposed its 16th consecutive dividend increase to EUR 1.25 per share. Management also highlighted an inaugural EUR 400 million share buyback authorization announced in January 2026, running through October 2026.
Strategy update: transformation progress and Care & Wellness
Parisot said the ONE Symrise Strategy is built on three pillars—portfolio, growth, and efficiency—supported by sustainability, digitalization, and people as key enablers. He described the ONE SYM Transformation as the execution engine and pointed to EUR 100 million in cumulative cost savings across 2024 and 2025, alongside a 280 basis point expansion in adjusted EBITDA margin over the same period.
Portfolio actions discussed on the call included divestments (including Aqua Feed and the Champon business) and the ongoing process to divest the Terpenes business. The company also referenced the acquisition of Probi, now integrated into a newly formed Care and Wellness division (reported as a division within the health and care segment as of January 1, 2026). Parisot said Care and Wellness serves a “structurally growing market” and expects the division to exceed EUR 500 million in sales in 2026.
2026 outlook: prudent near-term view, reaffirmed midterm targets
For full-year 2026, Symrise guided for organic sales growth of 2.0% to 4.0%, an adjusted EBITDA margin of 21.5% to 22.5%, and an adjusted business free cash flow margin of above 14%. The outlook assumes Q1 organic growth down low single digits year over year, which management attributed to tougher comparables, soft pockets of demand, and additional uncertainty from conflict in the Middle East.
In Q&A, Parisot said the 2026 organic growth is expected to be “mainly driven by volumes,” while noting he could not provide a precise split between price and volume ahead of time. He characterized the Q1 view as “prudent,” while reiterating confidence in meeting full-year guidance and pointing to a “very strong pipeline” and project activity with customers.
On regional exposure, Klinger said the core Middle East region accounts for roughly 3% of group turnover, approximately EUR 140 million to EUR 150 million, while adding that impacts on logistics and transportation were difficult to assess on a fast-changing basis.
Regarding energy costs within the margin outlook, Klinger said Symrise is “relatively less exposed,” describing energy costs at around 2.5% of sales and stating that about 80% is hedged.
Looking beyond 2026, Symrise reaffirmed its 2025–2028 targets of 5% to 7% annual organic sales growth, an EBITDA margin of 21% to 23%, and a business free cash flow margin of more than 14%, citing tailwinds such as regulation, clean-label and natural demand, reformulation activity, and emerging-market expansion.
About Symrise (ETR:SY1)
Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates through two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for fish feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.
